Cathepsin-L Ameliorates Cardiac Hypertrophy Through Activation of the Autophagy–Lysosomal Dependent Protein Processing Pathways

Mei Sun, MD, PhD; Maral Ouzounian, MD; Geoffrey de Couto, PhD; Manyin Chen, MD, MSc; Ran Yan, MD; Masahiro Fukuoka, MD, PhD; Guohua Li, MD; Mark Moon, MSc; Youan Liu, MD, MSc; Anthony Gramolini, PhD; George J. Wells, PhD; Peter P. Liu, MD

Background—Autophagy is critical in the maintenance of cellular protein quality control, the final step of which involves the fusion of autophagosomes with lysosomes. Cathepsin-L (CTSL) is a key member of the lysosomal protease family that is expressed in the murine and human heart, and it may play an important role in protein turnover. We hypothesized that CTSL is important in regulating protein processing in the heart, particularly under pathological stress.

Methods and Results—Phenylephrine-induced cardiac hypertrophy in vitro was more pronounced in CTSL-deficient neonatal cardiomyocytes than in controls. This was accompanied by a significant accumulation of autophagosomes, increased levels of ubiquitin-conjugated protein, as well as impaired protein degradation and decreased cell viability. These effects were partially rescued with CTSL1 replacement via adeno-associated virus–mediated gene transfer. In the in vivo murine model of aortic banding (AB), a deficiency in CTSL markedly exacerbated cardiac hypertrophy, worsened cardiac function, and increased mortality. Ctsl−/− AB mice demonstrated significantly decreased lysosomal activity and increased sarcomere-associated protein aggregation. Homeostasis of the endoplasmic reticulum was also altered by CTSL deficiency, with increases in Bip and GRP94 proteins, accompanied by increased ubiquitin–proteasome system activity and higher levels of ubiquitinated proteins in response to AB. These changes ultimately led to a decrease in cellular ATP production, enhanced oxidative stress, and increased cellular apoptosis.

Conclusions—Lysosomal CTSL attenuates cardiac hypertrophy and preserves cardiac function through facilitation of autophagy and proteasomal protein processing. (J Am Heart Assoc. 2013;2:e000191 doi: 10.1161/JAHA.113.000191)

Key Words: autophagy • cathepsin-L • lysosome • remodeling • ubiquitin-protein

Cardiac myocytes are long-lived postmitotic cells, and the regulation of cell size and the dynamic turnover of proteins are key mechanisms of adaptation to variations in workload and stress in the heart. Cellular pathways participating in cell growth, survival, and death are controlled by the steady-state level of regulatory proteins and enzymes, which result from the balance between protein synthesis and degradation. The rate of protein turnover also modulates protein damage and quality control, which in turn maintains the functional integrity of the cell. If this system is compromised, impaired protein degradation and abnormal protein accumulation may result in not only cellular dysfunction but also organ failure including cardiomyopathy.

The majority of proteins in eukaryotic cells are degraded via 2 proteolytic systems: the autophagy–lysosomal system and the ubiquitin–proteasome system (UPS). In cardiac muscle, these 2 systems are coordinated to preserve a carefully regulated composition of proteins and organelles. Proteasomes are thought to be responsible for the highly selective degradation of cellular proteins under basal metabolic conditions. Proteasome pathway targets soluble, short-lived proteins by ubiquitination followed by hydrolysis via the proteasome. In contrast, the autophagy–lysosomal pathway is responsible for the degradation of long-lived bulky cytosolic proteins and organelles altered under conditions of stress (macroautophagy). This is also accompanied by lysosomal sequestration and degradation of additional specific cytosolic proteins (microautophagy and chaperone-mediated autophagy).

Impaired or dysregulated protein degradation in the heart has recently been recognized as a potential major contributor...
to cardiac disease. While the UPS and autophagy pathways have largely been investigated separately,\textsuperscript{10,11} there likely are significant cross-talks and coordinations between these systems to optimize protein quality control. Cathepsin-L (CTSL) is a key member of the lysosomal protease family in the heart. Mice lacking CTSL spontaneously developed heart disease at 1 year of age that resembled many features of human dilated cardiomyopathy.\textsuperscript{12,13} We have previously shown that deficiency of lysosomal enzyme CTSL in the setting of ischemic injury caused exaggerated activation of UPS.\textsuperscript{14} We believe that CTSL, an important lysosomal protein–processing enzyme, may play a key role in maintaining the lysosomal degradation response to stress. Cardiac hypertrophy, a critical hallmark of stress remodeling, involves progressive alterations of intracellular components including myofibrillar protein assembly.\textsuperscript{15} The final step of the autophagy–lysosomal pathway is the fusion of an autophagosome with a functioning lysosome, and an imbalance of protein homeostasis by dysfunction of this system may lead to pathological hypertrophy and dysfunction. It has been reported that cardiac myocyte–specific expression of CTSL in a CTSL-deficient dilated cardiomyopathy mouse results in improved cardiac function.\textsuperscript{16} Although these observations suggested that changes in CTSL levels may cause altered cardiac function with stress, the importance of lysosomal proteases in cardiac protein turnover is still not well understood.

In the following sets of experiments, we examine how CTSL perturbation affects protein turnover and cardiac function in the setting of pressure-overload hypertrophy.

**Methods**

**Cell Culture**

Cardiac myocytes were isolated from the ventricles of 1-day-old neonatal mice. Myocytes were dissociated with 0.15% trypsin in (in mmol/L) NaCl 137, KCl 5.4, MgSO\(_4\) 0.8, dextrose 5.6, KH\(_2\)PO\(_4\) 0.4, Na\(_2\)HPO\(_4\)·7H\(_2\)O, and HEPES 20.06 mmol/L, pH 7.4. Cells were differentially plated for 1 hour to remove fibroblasts and other contaminating cell types. The cells were then resuspended in DMEM/F12 medium supplemented with 10% fetal bovine serum, gentamicin (100 IU/mL), and bromodeoxyuridine. Myocytes were plated at a density of 2×10\(^5\) cells/mL, and serum was withdrawn after 24 hours. The cells were then treated for the following.

**Detection of CTSL Enzyme Activity**

CTSL proteolytic activity was determined in tissue lysates (50 μg protein) by degradation of the fluoropeptide Z-Phe-Arg-4-methyl-coumarin-7-amide (20 μmol/L; Bachem) in the presence of the CTSB-specific inhibitor CA074 (1.5 μmol/L; Bachem) at a pH of 5.5. The release of 7-amino-4-methyl-coumarin was monitored continuously for 1 hour by spectrofluorometry at excitation and emission wavelengths of 360 and 460 nm.

**Western Blot Analysis**

Cardiac myocytes or cardiac tissue samples were homogenized with lysis buffer and diluted 1:1 with 2× SDS sample buffer (Invitrogen Novex). An equal amount of protein (20 μg) was loaded onto each lane of an 8% to 16% Tris-Glycin gel (Helixx). Proteins were separated by electrophoresis and transferred to a nitrocellulose membrane using an electroblotting apparatus (Invitrogen). Membranes were incubated with 5% BSA for 1 hour to decrease nonspecific binding. Samples were then incubated with the following primary antibodies overnight at 4°C: LC3 (MLB, Japan); ubiquitin and cytchrome c (Cell Signaling Technology); catespin-S (CTSS), catespin-D (CTSD), myosin, H-cadherin, and Connexin43 (Abcam, Inc); atrial natriuretic factor (ANF), heat shock protein (Hsp)70, green fluorescent protein (Gfp)94, and Grp78 (Stressgen, Bioreagents); Lamp-1 (Santa Cruz Biochemistry, Inc.); and human CTSL1 (Lifespan Biosciences, Inc.). Samples were washed and incubated with peroxidase-conjugated secondary antibody, and detected using the Amersham ECL detection kit.

**Immunofluorescent Staining of Myocytes**

Cultured neonatal myocytes were washed briefly with PBS and fixed with 4% paraformaldehyde/PBS for 10 minutes at room temperature. The cells were then rinsed with PBS and incubated with 10% BSA, followed by overnight incubation with primary antibodies against CTSL (BD Pharmingen Technical), α-actinin (Sigma), Lamp-1, LC3, and ubiquitin (P4D1; Cell Signaling Technology) at 4°C. The sections were then incubated with a matching fluorescent conjugated secondary antibody for 45 minutes at room temperature. Negative controls were performed for all immunologic staining by omitting the primary antibody.

**Reverse Transcription–Polymerase Chain Reaction**

Total RNA was extracted from cultured myocytes/tissues. Reverse transcription–polymerase chain reaction (RT-PCR) was performed with primers 5′-ATGTGCCGGACCTTGGAAAG-3′ (forward) and 5′-CCTCGGGTTAGCTGAGAGATCA-3′ (reverse) for mouse beta-myosin heavy chain (β-MHC) and 5′-CAT-GGCCCTCCGTCTCTCTA-3′ (forward) and 5′-CCTGCCTTACCACCTCTCTGAT-3′ (reverse) for mouse GAPDH. With PCR buffers and Taq1 polymerase, the cycle parameters were as follows:
denaturation at 95°C for 2 minutes, annealing at 60°C for 1 minute, and extension at 72°C for 2 minutes for 33 cycles with 5 minutes of final elongation at 75°C. Reaction mixture without template cDNA was used as a negative control.

**Myocyte Viability Assay**

The 3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay is based on the ability of mitochondria to reduce MTT, a yellow tetrazolium dye, to MTT formazan, a blue mitochondrial byproduct. The reduction is mediated by mitochondrial dehydrogenases that are present in living but not dead cells, and the assay is appropriate to assess the viability of mitochondria-rich cells. The myocytes were isolated as described here earlier and cultured in 200 μL of fresh DMEM/F12 supplemented with 20 μL of MTT (0.1 mg/mL) solution in a 96-well plate (10^4 cells/well). Four hours later, the supernatant was aspirated and 150 μL of DMSO was added to each well, and then the cells were incubated at 37°C for 10 minutes. The absorbance at 570 nm was then read for each well to determine myocyte viability (n=4).

**Protein Synthesis**

Protein synthesis by myocytes was assessed by determining the incorporation of L-[14C]phenylalanine (Phe; Amersham) into acid-insoluble proteins. Myocytes were incubated with serum-free DMEM/F12 supplemented with either unlabeled Phe 0.6 mmol/L, phenylephrine (PE) 100 μmol/L, or vehicle for 12, 24, and 48 hours, including 5 mCi/well L-[14C]Phe for the last 4 hours. An excess of unlabeled Phe (0.6 mmol/L) was used to ensure the equilibration of intracellular and extracellular specific radioactivity. At the end of a 4-hour labeling period, the cells were rapidly rinsed 3 times with ice-cold PBS. Cells were solubilized in 2% sodium dodecyl sulfate and precipitated with 2 mL of 20% ice-cold trichloroacetic acid (TCA). The precipitates were collected and washed sequentially with 10% and 5% TCA and finally with absolute ethanol. The radioactivity was determined in a Tri-Carb 4000 liquid scintillation counter (Packard Instruments), and the [14C]Phe incorporation was presented as disintegrations per minute per 10^5 cells. The cell protein synthesis rate was expressed as disintegrations per minute per well.

**Protein Degradation**

To measure the rate of protein degradation, myocytes were labeled by preincubating cells in serum-free DMEM containing 0.5 μCi/well L-[14C]Phe for 48 hours. To minimize the reincorporation of L-[14C]Phe, the experimental media contained an excess (2 mmol/L) of unlabeled Phe. After a 2-hour phase, the cells were washed with PBS to remove L-[14C]Phe released from the degradation of short-lived proteins, and 4 mL of fresh experimental medium containing PE (100 μmol/L) was added. At the indicated sampling periods up to 48 hours, 0.3-mL aliquots of the media were taken and precipitated by the addition of ice-cold TCA (10% final concentration). The samples were centrifuged for 5 minutes, and the TCA-soluble supernatant was frozen at −20°C overnight for the radioactivity measurement. At the end of each experiment, the cells were washed 3 times with ice-cold PBS. The radioactivity in the cells and in the media was measured as described here earlier. The initial L-[14C]Phe incorporation into cell proteins was calculated from the total radioactivity released plus the amount remaining within the cells at the end of the experiments. The protein degradation rate was calculated as the percentage of radioactivity released versus the radioactivity remaining in the cells at the indicated time intervals.

**Measurement of ATP**

The ATP levels of myocytes or heart tissue from Ctsl^−/− and Ctsl^+/− mice were measured using the Enzylight ATP Assay kit (BioAssay Systems US), which denotes ATP bioluminescence as a marker of mitochondrial activity. Briefly, the phenothiazines were dissolved in PBS and dispensed in 10 μL aliquots into 96-well microplates. The myocytes or fresh heart tissues were processed according to the manufacturer’s protocol. The luminescence produced by the luciferase-catalyzed luciferin plus ATP reaction was detected using a MicroLumat LB96P multiwell scanning spectrophotometer (EG&G Berthold). The data were then normalized to the control group. The percent decrease in ATP was calculated according to the decrease in luminescence compared with controls. Six independent experiments were carried out for each phenothiazine concentration, 1 experiment for each cell line, and 2 parallel samples for each phenothiazine concentration.

**Adeno-Associated Virus Vectors and Gene Transfer**

The full-length human CTSL1 gene was subcloned into the adeno-associated virus 9 (AAV9)–green fluorescent protein (GFP) system. CTSL1 was inserted upstream of the cytomegalovirus promotor into the AAV-9 shuttle vector (Vector Biolabs). Control virus (AAV-9 GFP alone) containing the cytomegalovirus-GFP sequence only was custom-made by Vector Biolabs. Neonatal ventricular myocytes were transfected with AAV9 constructs on the day of isolation. One hour after plating, AAV9-ACTSL1 at 1×10^7 viral genomes (VG)/well was added for 72 hours before further analysis.
Animal Model

Transverse aortic banding (AB) was performed in 10-week-old male (25 to 27 g) CTSL-deficient (B6×FSB/GnEia/aCtsflfs/J; Jackson Laboratory) and wild-type (Ctsl+/−) littermate control mice as described previously.18

Experimental Study 1

Animals were euthanized on postoperative weeks 2 and 8 (n=5 surviving animals per time point, per group). Hearts were harvested, rinsed with cold PBS, frozen, and stored at −80°C for immunohistochemical, biochemical, and histochemical studies.

Experimental Study 2

Cardiac function was assessed on postoperative weeks 2 and 8 (n=5 for sham per group, n=10 for AB per group) using echocardiography and on week 8 using LV pressure–volume loop acquisition (n=6 for sham per group, n=16 for AB per group). Animals were euthanized, and the hearts were perfusion-fixed and then sectioned for cardiac morphometric studies.

Immunohistochemistry

Cryostat sections (5 μm) were prepared, air-dried, and fixed in 4% paraformaldehyde in PBS. The sections were incubated with 0.3% hydrogen peroxide and 10% BSA, followed by a primary antibody against CTSL (BD PharMingen Technical) overnight at 4°C and then incubation with a matching biotinylated secondary antibody (Vector) or fluorescent conjugated secondary antibody for 45 minutes at room temperature. Negative controls were performed for all immunologic staining by omitting the primary antibody.

Isolation of Lysosomes and Measurement of Lysosomal Activity

Lysosomes were isolated using a lysosome isolation kit (Sigma) according to the manufacturer’s instructions. Lysosomal proteins were quantified by a Bradford protein assay, and their intactness was measured. The dye absorbance of a neutral red dye at 460 and 510 nm was measured, and the neutral red uptake was calculated.

LV Function

Eight weeks after the induction of AB, mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) and placed on controlled heating pads. Core temperature was measured with a rectal probe and maintained at 37±0.5°C. A microtip catheter transducer (SPR-839; Millar Instruments) was inserted into the right carotid artery and advanced into the left ventricle under pressure control. After 15 minutes of stabilization, the pressure and volume signals were recorded continuously with an ARIA pressure–volume conductance system coupled with a Powerlab/4SP A/D converter, stored, and displayed. PVAN software (Millar Instruments) was used for subsequent analysis of pressure–volume loops.

Cardiac Morphometry

Morphometric analysis was performed on cardiac sections using an image quantitative digital analysis system (National Institutes of Health Image 1.6). Relative ventricular cavity dimension and wall thickness were determined according to the method of Sun et al.19 Single myocytes were measured with images captured from hematoxylin and eosin–stained sections. The outline of 100 to 200 myocytes was traced in each section. Simple PCR image system software (Universal Imaging) was used to determine myocyte cross-sectional area.

Transmission Electron Microscopy

The hearts were removed and immediately fixed in half-strength Karnovsky’s fixative as 3-mm³ tissue cubes. The tissues were postfixed in 2% osmium tetroxide and embedded in araldite resin. Semithin sections were stained with toluidine blue/borax and examined by light microscopy. Ultrathin sections were stained with uranyl acetate and lead citrate and photographed using a Jeol 1200EX transmission electron microscope.20

Lipid Peroxidation

Determination of malondialdehyde (MDA) was carried out to estimate the extent of lipid peroxidation in the heart. Tissue samples were added to butylated hydroxy toluene (1 mg/mL of Tris-HCl 20 mmol/L), then frozen at −80°C until the assay was performed. After thawing, tissue samples were washed in ice-cold Tris-HCl 20 mmol/L, pH 7.4, minced in ice-cold Tris-HCl 20 mmol/L, and homogenized in a 1:10 weight/volume ratio with a Teflon pestle. After centrifugation at 3000g for 10 minutes at 4°C, the clear homogenate supernatant was used for the biochemical assay. The colorimetric commercial kit (lipid peroxidation assay kit; Calbiochem-Novabiochem Corporation) was performed to assay free MDA. The concentration of MDA was normalized to sample protein content.

Statistical Analysis

Statistical analyses were performed with GraphPad Prism 4.0. Survival between groups was compared by Kaplan–Meier survival analysis. All other comparisons were performed by nonparametric tests (Kruskal–Wallis test or Mann–Whitney test). The values are expressed as medians with 25th and 75th percentiles. Statistical significance is recognized at P<0.05.
Results
CTSL Activity Is Increased in Cardiac Myocytes With Hypertrophic Stimulation

PE stimulation led to an increase in the biological activity of CTSL in Ctsl+/+ myocytes compared with the control group without PE (Figure 1A). CTSL activity was not detected in Ctsl-/− myocytes with or without PE stimulation. Furthermore, wild-type myocytes exhibited low levels of CTSL at baseline (Figure 1B), mainly localized in the perinuclear region (Figure 1C-a). In contrast, after stimulation with PE 100 μmol/L for 48 hours, CTSL level was increased and expressed diffusely throughout the cytoplasm as well as in the cell periphery (Figure 1B and 1C-b).

Hypertrophic Stimulation Results in an Exaggerated Cellular Response in Ctsl−/− Myocytes

After PE stimulation, Ctsl−/− neonatal cardiac myocytes exhibited increased hypertrophy as indicated by a significantly

---

Figure 1. Isolated neonatal cardiac myocytes were treated with PE for 48 hours. A, CTSL activity measurements. B, Western blot detection and quantification of CTSL levels in Ctsl+/+ myocytes. C, Immunofluorescent staining for CTSL. D, Detection of β-MHC mRNA by RT-PCR and ANF protein by Western blotting. E, Myocyte area measurements. F, Cellular protein content. G, Immunofluorescent staining for α-actinin. H, MTT assay for the cell viability. The values are expressed as medians with 25th and 75th percentiles (the bar indicates the median value and the line indicates the 25th and 75th percentiles; n=4). #P<0.05 vs control, *P<0.05 vs Ctsl+/+ PE treatment. PE indicates phenylephrine; CTSL, cathepsin-L; β-MHC, beta-myosin heavy chain; RT-PCR, reverse transcription–polymerase chain reaction; ANF, atrial natriuretic factor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
increased expression of fetal genes ANF and β-MHC (Figure 1D), larger myocyte area (Figure 1E), and increased cellular protein content (Figure 1F). Immunofluorescent analysis of the Ctsl+/− myocytes after PE stimulation for 48 hours demonstrated patchy aggregates and disorganization of the cytoskeletal protein α-actinin compared with Ctsl+/+ myocytes (Figure 1G). These changes were also associated with decreased cell viability (Figure 1H). These results suggest that CTSL acts as a negative regulator of the cardiac hypertrophy process in response to PE stimulation.

CTSL Is Required for Completing Autophagic Flux in Cardiac Myocytes With Hypertrophic Stimulation

Levels of LC3-II, an autophagosome activation marker,21 were increased in Ctsl−/− myocytes after 48 hours of PE treatment compared with Ctsl+/+ controls (Figure 2A). This was accompanied by increased accumulation of LC3-positive vesicles on immunofluorescence analysis (Figure 2B). Clearance of autophagosomes occurs via fusion with lysosomes, followed by

**Figure 2.** A, Representative Western blot and quantification of LC3 level after 48 hours of PE treatment. B, Immunofluorescent staining for LC3 (a through d), Lamp1 (e through h) and merged (i through l) in Ctsl+/+ (a, e, i) and Ctsl−/− (b, f, j) control groups, and Ctsl+/+ (c, g, k) and Ctsl−/− (d, h, i) after 48 hours of PE treatment. The arrows show the accumulation of large autophagosomes in PE-treated Ctsl−/− myocytes. C, Western blot detection and quantification of p62 levels in Ctsl+/+ and Ctsl−/− myocytes treated with PE, bafilomycin A1 (Baf), and Baf recovery (Baf/RC). Values are expressed as medians with 25th and 75th percentiles (n=4). #P<0.05 vs control, *P<0.05 vs Ctsl+/+ PE treatment. LC3 indicates microtubule-associated protein 1 light chain 3; PE; phenylephrine; CTSL, cathepsin-L.
the degradation of autophagolysosomal content. To determine whether CTSL deficiency affected autophagosome–lysosome fusion and degradation, we analyzed LC3-II and lysosomal membrane protein (Lamp1) colocalization in myocytes before and after PE treatment. Under basal conditions, LC3-II and Lamp1 colocalized in Ctsl+/+ myocytes, and this pattern of staining was similar in the Ctsl−/− myocytes (Figure 2B-i, j). After PE stimulation, the LC3-positive autophagosomes and Lamp1-positive lysosomes showed an increase in both groups (Figure 2B-k, l), but this was more pronounced in Ctsl−/− myocytes. However, the colocalization pattern did not differ significantly between the 2 groups. These data suggest that the formation of autophagosomes and the fusion of autophagosome with lysosomes were not impaired by CTSL deficiency following hypertrophic stimulation. Accumulation of autophagosomes was likely due to defective clearance caused by lack of CTSL, leading to impaired lysosomal activity.

In addition, impaired autophagy–lysosomal degradation in PE-treated Ctsl−/− cardiac myocytes is reflected by the significantly increased level of p62, an adapter protein critical for bridging ubiquitinated protein to autophagosomes (Figure 2C). To further validate that deficiency of CTSL caused an impairment of autophagic activity and degradation, we monitored autophagic flux using bafilomycin A1 (Baf), a lysosomal inhibitor, in Ctsl+/+ and Ctsl−/− myocytes. The results showed that p62 levels were increased in both PE-treated and nontreated cardiac myocytes. However, in Ctsl−/−, the level of p62 showed further enhancement on Baf treatment, which reduced to the normal level after Baf removal. However, p62 level remained high in Ctsl−/− myocytes despite the removal of Baf. In the absence of CTSL, extra-autophagosomes accumulated in the myocytes, which further exaggerated the hypertrophy response (Figure 2B-d). These findings indicate impairment of lysosomal degradation and retardation of autophagic flux in Ctsl−/− due to deficiency of CTSL.

**Decreased Protein Processing and Turnover in Ctsl−/− Myocytes With PE Stimulation**

The autophagy–lysosomal pathway plays an important role in cellular protein turnover, particularly under stress. Cardiac myocyte protein synthesis and degradation were investigated in cells exposed to PE (100 μmol/L). As seen in Figure 3A, PE stimulated the incorporation of L-[3H]Phe into cells in a time-dependent manner (up to 48 hours) in both PE-treated Ctsl+/+ and Ctsl−/− myocytes. This shows no significant difference in incorporation (Figure 3A-a) between groups. However, the rates of protein degradation, as reflected by L-[3H]Phe release, were significantly decreased in Ctsl−/− compared with Ctsl+/+ PE-treated myocytes between time periods of 32 to 48 hours (Figure 3A-b).

**Effect on Ubiquitin-Proteasome in Ctsl−/− Myocytes After Hypertrophic Stimulation**

UPS and selective autophagy are 2 major pathways regulating proteolysis and protein quality control. A defect in either system could result in ubiquitinated protein aggregated as seen in the CTSL-deficient myocytes. In this study, the ubiquitinated proteins were significantly accumulated in CTSL-deficient myocytes, especially after PE stimulation (Figure 3B). The immunostaining detected the ubiquitin-positive protein distribution in both the cytoplasm and nucleus of stimulated Ctsl−/− myocytes (Figure 3C). This raises the possibility that deficiency of CTSL impairs the clearance of misfolded proteins and results in the accumulation of ubiquitinated protein aggregates. However, it could also be the result of increased activation of the UPS pathway due to the defect in autophagy–lysosomal degradation pathway. Therefore, 20S proteasomal activity was measured. As seen in Figure 3D, there were significantly high levels in both control and PE-treated myocytes in Ctsl−/− compared with Ctsl+/+. Therefore, the increased UPS activity in CTSL deficiency is a compensatory mechanism to overcome the impairment of autophagy–lysosomal degradation.

**Restoration of Protein Processing by AAV9-Mediated CTSL1 Transfer In Vitro**

To evaluate further the specificity of CTSL on protein processing and determine the potential therapeutic value of CTSL gain of function, we expressed human CTSL1 through an AAV9 viral delivery system in Ctsl−/− myocytes. Immunostaining using human CTSL1 antibody detected the CTSL1 expression in transfected Ctsl−/− myocytes (Figure 4A). The CTSL activity assay showed potential recovery of CTSL activity in the Ctsl−/− AAV9-CTSL1–transduced myocytes and was further upregulated by PE treatment (Figure 4B). Moreover, the impairment in protein turnover caused by CTSL deficiency was partially rescued. As shown in Figure 4C, protein degradation rate was significantly increased in Ctsl−/− gene–transduced myocytes. Myocyte size was also significantly reduced compared with the nontransduced group (Figure 4D), together with improved α-actinin organization (Figure 4E).

**Increased Cardiac CTSL Expression and Activity After AB**

To evaluate the role of CTSL in cardiac remodeling in vivo, mice were subjected to AB. As shown in Figure 5A, cardiac CTSL expression was detected by immunohistochemistry in myocytes, endothelial cells, smooth muscle cells, and fibroblasts. After AB, CTSL expression was increased in all cell types, especially in cardiomyocytes. CTSL protein levels were
also confirmed by Western blotting (Figure 5B). High levels of CTSL activity were also maintained to 8 weeks post AB in Ctsl+/+ mice but were not detectable in Ctsl−/− mice (Figure 5C).

Changes in Cathepsin Family Members in Hearts Subjected to AB

To determine whether CTSL deficiency induced compensatory changes in other members of the cathepsin family, we evaluated cathepsin-S and -D by Western blot analysis. As shown in Figure 5D, there was no change in cathepsin-S levels with or without AB in both groups. However, increased levels of cathepsin-D were observed at baseline in Ctsl−/− compared with Ctsl+/+ mice. After AB, cathepsin-D levels were increased in Ctsl+/+ mice but did not increase further in Ctsl−/− mice.

CTSL Deficiency Impaired Lysosomal Activity, Leading to Myofilament Disorganization and Aggregate Formation in Response to AB

As expected, there was reduced lysosomal neutral red uptake, indicating impaired lysosomal function22–24 in Ctsl−/− mice compared with Ctsl+/+ controls (Figure 5E). In addition,
although lysosomal activity was upregulated post AB, the relative increase in neutral red uptake is still significantly lower in the Ctsl−/− compared with the Ctsl+/+ group (Figure 5E). Confocal microscopy and immunohistochemical analyses of heart sections revealed an orderly arrangement of cytoskeletal proteins in Ctsl+/+ cardiac myocytes post AB. In contrast, cytoskeletal proteins α-actinin and myosin were disorganized and aggregated in clumps in Ctsl−/− AB mice (Figure 5F). Western blot analysis and quantification demonstrated increased levels of myosin, Connexin43, and H-cadherin in Ctsl−/− hearts compared with Ctsl+/+ mice (Figure 5G) after AB.
CTSL Deficiency Worsened Ventricular Remodeling and Heart Failure in Response to AB

AB resulted in cardiac hypertrophy in both Ctsl<sup>+/+</sup> and Ctsl<sup>−/−</sup> mice within 2 weeks but was exaggerated in Ctsl<sup>−/−</sup> mice (Figure 6A). As expected, the heart weight–to–body weight ratio of Ctsl<sup>−/−</sup> mice increased by 36%, and the size of LV myocytes increased by 33% post AB. In comparison, the heart weight–to–body weight ratio was increased by 78% and LV myocyte size increased by 72% (P<0.01) in Ctsl<sup>−/−</sup> mice post
AB (Figure 6B). Lung weight-to-body weight ratio was also significantly increased post AB in both groups, especially in Ctsl−/− mice (Figure 6C). The lungs of Ctsl+/+ mice showed mild edema and cellular infiltration in the alveolae post AB (Figure 6C). On the other hand, the alveolar septa appeared thickened and the alveolar space contained numerous cells and edema in Ctsl−/− mice (Figure 6C). More robust increases in ANF protein level and β-MHC mRNA expression were observed in Ctsl−/− mice, with high levels persisting at 8 weeks post AB (Figure 6D and 6E).

**Figure 6.** A, Representative gross morphology of whole hearts, corresponding coronal sections (scale bar, 2 mm), and H&E staining of hearts 8 weeks post sham and AB surgery. B, Quantitative data of heart weight-to-body weight ratio and myocyte area (n=16). C, Lung-to-body weight ratio (n=16) and H&E staining of lung tissue 8 weeks post AB. D, Western blot detection and the quantification of cardiac ANF levels (n=4). E, RT-PCR detection for β-MHC mRNA expression (n=4). F through E: #P<0.05 vs sham group; *P<0.05 vs Ctsl+/+ AB groups. F, Kaplan–Meier survival curves in Ctsl+/+ (n=65) and Ctsl−/− (n=96) mice after AB or sham-operation (n=30/group). *P<0.001 vs Ctsl−/−. G, Representative M-mode echocardiograms of Ctsl+/+ and Ctsl−/− mice 8 weeks post sham and AB surgery. H, In vivo hemodynamic measurements: left ventricular endsystolic pressure (LVESP), LV end-diastolic pressure (LVEDP), peak rates of pressure rise (+dP/dt) and pressure fall (–dP/dt), and ejection fraction (EF) 8 weeks post sham surgery (n=6) or AB (n=16) in Ctsl+/+ and Ctsl−/− mice. #P<0.05 vs sham group; *P<0.05 vs Ctsl+/+ AB groups. Values are expressed as medians with 25th and 75th percentiles. CTSL indicates cathepsin-L; AB, aortic banding; ANF, atrial natriuretic factor; H&E, hematoxylin and eosin; β-MHC, beta-myosin heavy chain; RT-PCR, reverse transcription–polymerase chain reaction.
genotype (data not shown), but there was a significantly lower survival rate in the Ctsl−/− mice compared with the Ctsl+/+ mice (Figure 6F). Survival rate at 8 weeks was 86% and 50% for Ctsl+/+ and Ctsl−/− mice, respectively (*P<0.001).

M-mode echocardiography revealed exacerbated LV dilation in response to AB in Ctsl−/− mice (Figure 6G). As early as 2 weeks post AB, the thickness of the interventricular septum and the LV posterior wall, as well as LV end-systolic and -diastolic diameters, were all increased compared with Ctsl+/+ mice (Table 1). Cardiac dysfunction was further confirmed by in vivo hemodynamic measurements. Ctsl−/− AB mice had lower LV end-systolic pressure, higher LV end-diastolic pressure, and markedly depressed LV systolic and diastolic dP/dt values compared with Ctsl+/+ AB mice (Figure 6H). Reduced −dP/dt and increased LV end-diastolic pressure suggested diastolic dysfunction in Ctsl−/− mice post AB (Figure 6H).

CTSL Deficiency Causes Increased Hsp70 and Ubiquitinated Proteins in Response to AB

Hsps, including Hsp70, are molecular chaperones that attempt to refold misfolded proteins and prevent the accumulation of cytoplasmic protein aggregates. In the present study, Hsp70 levels were significantly increased in banded Ctsl−/− mice (Figure 7A). In Ctsl+/+ mice, the 40-kDa ubiquitin protein levels were increased significantly after 8 weeks of AB (Figure 7B and 7C). In contrast, the 40-kDa ubiquitin protein levels in Ctsl−/− mice were significantly increased at 1 and 2 weeks and decreased dramatically after

Figure 6. Continued
8 weeks (Figure 7B and 7C). This decrease in 40-kDa ubiquitin was accompanied by an increase in high molecular weight conjugated ubiquitin, depicted in Figure 7B. Densitometry revealed a 92.4% and 44.9% increase in conjugated ubiquitin protein levels after 8 weeks of AB in Ctsl
tiltilti/C0/tiltilti and Ctsl+/+ mice, respectively, compared with sham operated mice (Figure 7D). S20 proteasome activity analysis presented a significantly high level in both sham and AB conditions compared with Ctsl+/+ mice (Figure 7E). Therefore, the increased levels of ubiquitinated proteins in Ctsl−/− hearts following AB suggest a possibility of compensatory mechanism to overcome the impairment of autophagy–lysosomal pathway.

Ultrastructural and Biochemical Alterations in CTSL-Deficient Mice in Response to AB

The tissue ultrastructure of Ctsl+/+ AB hearts showed little vacuolation and an absence of abnormal lysosomal accumulation (Figure 7F-a). In contrast, an aberrant myocardial ultrastructure was observed in Ctsl−/− AB myocardium, characterized by the accumulation of numerous end-stage lysosomes with high electron density deposits (Figure 7F-b), accompanied by a robust accumulation of vacuolation (Figure 7F-c) and autophagosomes (Figure 7F-d through f). Furthermore, swelling and degeneration of the mitochondrial matrix (Figure 7F-g, h, i) with disorganized myocyte filament fibers (Figure 7F-j) were observed in these myocytes. An increased ratio of LC3-II/LC3-I and p62 levels in Ctsl−/− mice demonstrated an impairment of autophagy–lysosomal response to pressure overload (Figure 7G), which were confirmed in our in vitro studies. Western blot analysis showed increased levels of GRP78 and GRP94 in Ctsl−/− mice post AB (Figure 7G), suggesting that these 2 stress proteins work in concert during the folding and assembling of proteins.25 Neither protein nor ultrastructural changes were apparent in the myocardium of Ctsl+/+ AB cardiac myocytes.

Table 1. M-Mode Echocardiography Data 2 and 8 Weeks Post AB

|          | Ctsl+/+ | Ctsl−/− |
|----------|---------|---------|
|          | Sham    | AB      | Sham    | AB      |
|          | 2 wk    | 8 wk    | 2 wk    | 8 wk    |
| LVEDD, mm|         |         |         |         |
| Median   | 3.57    | 4.15    | 4.5*    | 3.62    | 4.7*    | 6.14*†  |
| (25% to 75%) | 3.28 to 3.73 | 3.89 to 4.28 | 4.2 to 5.0 | 3.31 to 3.7 | 4.3 to 4.86 | 5.83 to 6.37 |
| LVESD, mm|         |         |         |         |
| Median   | 2.09    | 2.59*   | 2.82*   | 2.11    | 3.24*†  | 4.57*†  |
| (25% to 75%) | 1.73 to 2.33 | 2.47 to 2.71 | 2.48 to 3.48 | 1.79 to 2.51 | 3.05 to 3.3 | 4.4 to 5.15 |
| IVSd, mm |         |         |         |         |
| Median   | 0.53    | 0.66    | 0.78*   | 0.61    | 0.87*†  | 0.92*†  |
| (25% to 75%) | 0.50 to 0.66 | 0.59 to 0.72 | 0.71 to 0.87 | 0.58 to 0.66 | 0.81 to 0.92 | 0.87 to 0.98 |
| PWd, mm  |         |         |         |         |
| Median   | 0.58    | 0.71    | 0.89*   | 0.59    | 0.87*†  | 1.27*†  |
| (25% to 75%) | 0.55 to 0.63 | 0.66 to 0.77 | 0.82 to 0.99 | 0.56 to 0.68 | 0.8 to 0.97 | 1.12 to 1.39 |
| % FS     |         |         |         |         |
| Median   | 42.4    | 37.3    | 36.5*   | 39.55   | 28.15*  | 21.7*   |
| (25% to 75%) | 33.9 to 45.7 | 34 to 40 | 26 to 42 | 31.5 to 47.5 | 26.2 to 29.5 | 1.12 to 1.39 |
| HR, /min |         |         |         |         |
| Median   | 532     | 542     | 494     | 554     | 558     | 542     |
| (25% to 75%) | 460 to 560 | 487 to 556 | 429 to 543 | 521 to 566 | 507 to 579 | 453 to 573 |
| N        | 5       | 10      | 10      | 5       | 10      | 10      |

Two-dimensionally guided M-mode echocardiography and hemodynamics were studied at 2 and 8 weeks post AB. AB indicates aortic banding; Ctsl, cathepsin-L; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVSd, diastolic interventricular septal thickness; PWd, diastolic posterior wall thickness; FS, fractional shortening; HR, heart rate; N, animal number.

*P<0.05 vs sham group.
†P<0.05 vs Ctsl+/+ AB groups.
**Discussion**

Growing evidence suggests that impairment of the lysosomal system may lead to the accumulation of abnormal proteins in severe cardiomyopathy and aging. \(^{12,13,26,27}\) These observations prompted us to examine the lysosomal protease CTSL as a modulator of protein turnover. Our current study...
Figure 7. Continued
demonstrates that CTSL plays an important role in protecting against cardiac dysfunction following pressure overload via activation of the autophagy–lysosomal pathway coordinated with the UPS, thus regulating protein turnover and cellular homeostasis.

Pathological cardiac hypertrophy is a major predictor of heart failure, which is itself associated with a mortality of 25% to 30% at 1 year.28,29 Despite the importance of hypertrophy as a prelude to heart failure, mechanisms governing this transition remain poorly understood. Autophagy has recently been recognized to play a critical role in the regulation of cardiac remodeling in response to stress.30,31 Increases in autophagy have been observed in cardiac disease31 and have been correlated with accelerated cell death and heart failure.30

CTSL is thought to participate in the lysosomal proteolytic processes, a role supported by its endosomal and lysosomal localizations, as well as its redundant substrate specificities within the heart. In support of this theory, in vitro study found that hypertrophic stimulation with PE led to a significantly increase in cellular CTSL expression and activity (Figure 1). These alterations may be part of the cell’s compensatory response to maintain intracellular homeostasis in response to hypertrophic stimuli. CTSL deficiency led to reduction of lysosomal activity, with accumulation of autophagosomes, and evidence of degradation of the autophagolysosomal content is impaired (Figure 2). A considerable accumulation of ubiquitinated proteins was observed in CTSL-deficient myocytes in response to PE, compensated with increased UPS activity, suggesting the coordinated involvement of the UPS. Furthermore, CTSL-deficient myocytes showed significant hypertrophic changes with aggregation of cellular filaments, as well as a decrease in cellular protein degradation rate and cell viability (Figure 3). These observations were confirmed with the partial rescue of the Ctsl<sup>−/−</sup> protein degradation rate and hypertrophic responses by the AAV9-mediated human CTSL<sup>+</sup> gene transfer (Figure 4). These data suggested that an alteration of the lysosomal activity by CTSL deficiency resulted in impairment of protein processing.

The in vivo murine model of pressure overload–induced hypertrophy furthered our understanding of the role of CTSL in mammalian cardiac remodeling. Consistent with the results of in vitro study, pressure overload induced robust expression and activation of CTSL in the hearts of wild-type mice. In contrast, CTSL-deficient mice had a compensated upregulation of cathepsin-D levels, thus maintaining some degree of basal lysosomal function under physiological conditions without major impairment in cellular function. However, under the stress of pathological hypertrophy, cathepsin-D levels failed to further elevate and were unable to compensate for the CTSL deficiency. Impaired lysosomal function (Figure 5) may result in the accumulation of autophagosomes and insufficiently digested proteins. The alterations of sarcomeric and cytoskeletal components observed in this study may account for the impaired generation and transmission of cardiac force in these mice.13 The rapid and significant increase in cardiac mass and features of heart failure in Ctsl<sup>−/−</sup> mice under pressure overload indicated that CTSL plays a critical role in the response to pathological stress by maintaining protein homeostasis.32

Intracellular protein turnover and protein quality control are regulated through lysosomal proteinolysis and the UPS3 and may partially compensate for each other.33–36 The proteolytic function of the UPS often becomes inadequate in proteinopathies, which in turn leads to activation of autophagy to remove abnormal protein, especially those in aggregated forms. Impairment of the autophagy–lysosomal pathway due to CTSL deficiency caused an increase in protein ubiquitination by the UPS. However, these proteins aggregated in the cardiac myocyte (Figure 7) and were unable to be cleared.37 Therefore, integration of the UPS and autophagy systems seems to be dependent on the integrity of lysosomal function.35 Dysregulated autophagy may contribute to the pathogenesis of heart disease,38,39 including heart failure.37,40 We have shown here that an early increase in autophagic vacuole formation is observed in Ctsl<sup>−/−</sup> hearts after AB. This lack of CTSL led to decreased lysosomal proteolytic activities, impaired lysosomal fusion and/or autophagosomal content degradation, autophagosome accumulation, and mitochondrial dysfunction, ultimately leading to cellular dysfunction and loss.41–45

Intracellular accumulation of proteins may disrupt homeostasis and lead to organelle toxicity. Mitochondria, which continually undergo remodeling, are the major source of ATP in the heart and are tightly associated with mechanical performance.46,47 In Ctsl<sup>−/−</sup> AB mice, we observed a decrease in cellular ATP along with abnormal mitochondrial structures, suggesting a functional link between the 2. Abnormal mitochondrial accumulation can lead to the release of proapoptotic factors, which enhances oxidative stress and leads to protein oxidation, DNA breaks, and lipid peroxidation.35 As increased reactive oxygen species generation was observed in the hearts of CTSL-null mice,12 we have also shown that its activation is further increased after AB, which may be the result of disrupted endoplasmic reticulum (ER) homeostasis.39 Post AB, ER molecular chaperones BiP/GRP78 and GRP94, as well as the non-ER chaperone HSP70, were elevated in Ctsl<sup>−/−</sup> mice. These findings suggest CTSL deficiency leads to ER stress that contributes to cardiac dysfunction and cellular apoptosis. Together, these data indicate a compensatory chaperone-mediated mechanism for the defective lysosomal function observed in CTSL-deficient mice (Figure 7).

In conclusion, mice with CTSL deficiency demonstrated an accelerated response to pathological stress resulting in
exacerbated cardiac hypertrophy and dysfunction. This was associated with the defective lysosomal function, leading to an impairment of the autophagy–lysosomal pathway, and ultimately resulting in impaired protein degradation and intracellular homeostatic remodeling (Figure 8). By maintaining lysosomal function and ensuring adequate protein quality control, CTSL plays an integral role in the remodeling response of the heart to stress.

Acknowledgment
We thank Xin Chen and Liyong Zhang for preparing reagents for revision experiments.

Sources of Funding
This work was funded by the Canadian Institutes of Health Research (MOP-43865, 13392, 49413) and the Heart and Stroke Foundation (T-6281). Dr. Gramolini is recipient of a Canada Research Chair award.

Disclosures
None.

References
1. Sandri M. Autophagy in health and disease: 3. Autophagy involvement in muscle atrophy. Am J Physiol Cell Physiol. 2010;298:C1291–C1297.
2. Zhao J, Braut JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007;6:472–483.
3. Su H, Li F, Ranek MJ, Wei N, Wang X. COP9 signalosome regulates autophagosome maturation. Circulation. 2011;124:2117–2128.
4. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhlin SV, Stitt TN, Patterson C, Latres E, Glass DJ. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007;6:376–385.
5. Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest. 2007;117:2486–2495.
6. Cohen S, Braut JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol. 2009;185:1083–1095.
7. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.
Cathepsin-L and Protein Turnover

Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Monnig G. DOI: 10.1161/JAHA.113.000191

12. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Monnig G.

13. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA.

14. Sun M, Chen M, Liu Y, Fukuoka M, Zhou K, Li G, Dawood F, Gramolini A, Liu PP.

15. Machackova J, Barta J, Dhalla NS. Myo.

16. Spira D, Stypmann J, Tobin DJ, Petermann I, Mayer C, Hagemann S, Vasiljeva.

17. Chaanine AH, Kalman J, Hajjar RJ. Cardiac gene therapy.

18. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum.

19. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac inflammation and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. Faseb J. 2006;20:1266–1286.

20. Sun M, Yokoyama M, Ishiwata T, Asano G. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Circulation. 2007;115:1398–1407.

21. Kuma A, Matsui M, Mizushima N. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy. 2007;3:323–328.

22. Butler D, Brown QB, Chin DJ, Batey L, Karim S, Mutneja MS, Kariana NA, Bahr BA. Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res. 2005;8:227–936.

23. Zurita JL, Jos A, del Peso A, Salguero M, Lopez-Artiguez M, Repetto G. Ecotoxicological evaluation of the antimalarial drug chloroquine. Toxicol In Vitro. 2001;15:363–368.

24. Melnick J, Aviel S, Argon Y. The endoplasmic reticulum stress protein GRP94, in addition to BiP, associates with unassembled immunoglobulin chains. J Biol Chem. 1992;267:13003–13006.

25. Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang QG, Ma WZ, Wang W. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med. 2008;87:249–260.

26. Malicdan MC, Noguchi S, Nonaka I, Safigt P, Nishino I. Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuroumscl Disord. 2008;18:521–529.

27. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269.

28. Owane TE, Hodge DQ, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.

29. McCormick J, Knight RA, Barry SP, Scarabelli TM, Abounit K, Latchman DS, Stephanou A. Autophagy in the stress-induced myocardium. Front Biosci (Elite Ed). 2012;4:2131–2147.

30. Chiong M, Wang ZY, Pedrozo Z, Cao D, Troncoso R, Ibacache M, Criollo A, Nemchenko A, Hill JA, Lavandero S. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011;2:e244.

31. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 2008;23:160–170.

32. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 2008;131:1949–1978.

33. Doherty FJ, Osborn NJ, Wassell JA, Heggie PE, Laszlo LR, Mayer RJ. Ubiquitin-protein conjugates accumulate in the lysosomal system of fibroblasts treated with cytosine proteinase inhibitors. Biochem J. 1989;263:45–55.

34. Marques C, Pereira P, Taylor A, Liang JN, Reddy VN, Szewda LI, Shang F. Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in cultured epithelial cells. FEBS Lett. 1999;452:1424–1426.

35. Pandey UB, Nie Z, Batlley Y, McCray BA, Rishton GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Pineda-Rubio H, Ruhl M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859–863.

36. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovemark WP, Schaper J. Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 2003;92:715–724.

37. Berry DL, Baehrecke EH. Autophagy functions in programmed cell death. Autophagy. 2008;4:359–360.

38. Nishida K, Kyo S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009;16:31–38.

39. He K, Hoon J, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovemark WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003;107:984–991.

40. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol. 2001;2:211–216.

41. Stromhaug PE, Klionsky DJ. Approaching the molecular mechanism of autophagy. Traffic. 2001;2:524–531.

42. Ciechanover A. Intracellular protein degradation: from a vague idea thru the discovery of the ubiquitin-proteasome and onto human diseases and drug targets. Cell Death Differ. 2005;12:1178–1190.

43. Pattison JS, Osisnka H, Robbins J. Atg7 induces basal autophagy and rescues deficiency in CryABR120G cardiomyocytes. Circ Res. 2011;109:151–160.

44. Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR, Day SM. Ubiquitin proteasome dysfunction in hypertrophic and dilated cardiomyopathies. Circulation. 2010;121:1004–1004.

45. Alcocirovic Z, Zhu G, Tanaka K. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005;115:547–555.

46. Alcocirovic Z, Zhu G, Tanaka K. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005;115:547–555.

47. Alrerek DD, Zlatkovic Lindor J, Yamada S, Terziek A. K(IAP) channel-dependent metaproteome decoded: systems approaches to heart failure prediction, diagnosis, and therapy. Cardiovasc Res. 2011;90:258–266.